All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What are the key considerations in managing pregnancy in MPN?

Apr 7, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

During the European School of Hematology (ESH) 3rd How to Diagnose and Treat: CML/MPN conference, the MPN Hub was pleased to speak to Elisabetta Abruzzese, Sant’Eugenio Hospital, Rome, IT. We asked, What are the key considerations in managing pregnancy in myeloproliferative neoplasms (MPN)?

What are the key considerations in managing pregnancy in MPN?

Elisabetta Abruzzese opens by discussing the increased need for effective treatment strategies for pregnant patients with MPN. Increasing rates of early diagnosis during reproductive years combined with the general trend of later pregnancies both contribute to this need. Abruzzese goes on to outline the risks associated with pregnancy in MPN, including thrombosis and hemorrhage both during and post-partum. The indication for additional therapies to reduce these risks as opposed to discontinuing any current treatment is noted. The interview concludes with a discussion on the appropriate therapeutics for use in essential thrombocytopenia, polycythemia vera, and myelofibrosis.

Your opinion matters

How would you define myelofibrosis treatment failure? A. A lack of spleen reduction B. A lack of symptom reduction C. A lack of either spleen or symptom reduction D. Symptom relief deemed inadequate by the patient
2 votes - 15 days left ...


Subscribe to get the best content related to MPN delivered to your inbox